STOCK TITAN

Dyne Therapeutics CEO sells 5,513 shares for taxes

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Dyne Therapeutics, Inc. (DYN) CEO & President John Cox had 5,513 common shares automatically sold on November 13, 2026, at a weighted average price of $16.82 per share to satisfy tax-withholding obligations tied to restricted stock unit vesting. The sale was not discretionary.

After the sale, Cox reported direct holdings of 351,994 shares, including 227,983 unvested RSUs. Four indirect trust holdings were each reported as 18,000 shares; the footnote says the shares are held in trust for the benefit of a child of Cox.

Insider Cox John
Role CEO & President
Sold 5,513 shs ($93K)
Type Security Shares Price Value
Sale Common Stock F1, F2, F3 5,513 $16.82 $93K
Holding Common Stock F4 -- -- --
Holding Common Stock F4 -- -- --
Holding Common Stock F4 -- -- --
Holding Common Stock F4 -- -- --
Holdings After Transaction: Common Stock — 351,994 shares (Direct); Common Stock — 18,000 shares (Indirect, By Trust #1); Common Stock — 18,000 shares (Indirect, By Trust #2); Common Stock — 18,000 shares (Indirect, By Trust #3); Common Stock — 18,000 shares (Indirect, By Trust #4)
Footnotes (4)
  1. F1. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $16.50 to $17.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
  3. F3. Includes 227,983 unvested RSUs.
  4. F4. These shares are held in a trust for the benefit of a child of the Reporting Person.
Shares sold 5,513 shares Automatic sale on November 13, 2026, to satisfy tax-withholding obligations
Weighted average sale price $16.82 per share Shares were sold in multiple transactions
Sale price range $16.50 to $17.02 per share Inclusive range for the multiple transactions
Direct shares after sale 351,994 shares Reported after the November 13, 2026 sale; includes 227,983 unvested RSUs
Shares held by each trust 18,000 shares Four indirect trust holdings were reported, each for the benefit of a child of Cox
Unvested RSUs 227,983 shares Included in Cox's reported direct holdings after the sale
restricted stock units technical
"vesting of restricted stock units granted to the Reporting Person"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Rule 10b5-1 regulatory
"consistent with the affirmative defense to liability under Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many DYN shares did John Cox sell, and at what price?

John Cox's 5,513 shares were sold at a weighted average price of $16.82 per share on November 13, 2026. The shares were sold in multiple transactions at prices from $16.50 to $17.02, inclusive.

Why were John Cox's DYN shares sold automatically?

The automatic sale was provided for in an agreement for restricted stock units granted to Cox on February 12, 2026, to satisfy tax-withholding obligations. The agreement constituted a binding contract consistent with the affirmative defense to liability under Rule 10b5-1; the sale was not discretionary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cox John

(Last)(First)(Middle)
C/O DYNE THERAPEUTICS, INC.
1560 TRAPELO ROAD

(Street)
WALTHAM MASSACHUSETTS 02451

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Dyne Therapeutics, Inc. [ DYN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
CEO & President
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/13/2026S(1)5,513D$16.82(2)351,994(3)D
Common Stock18,000IBy Trust #1(4)
Common Stock18,000IBy Trust #2(4)
Common Stock18,000IBy Trust #3(4)
Common Stock18,000IBy Trust #4(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $16.50 to $17.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
3. Includes 227,983 unvested RSUs.
4. These shares are held in a trust for the benefit of a child of the Reporting Person.
/s/ Ron Caponigro, Attorney-in-Fact11/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading